The company said net sales for Q3 2025 rose $879 million, or 10% on a reported basis and 5% organically. Diluted EPS was $1.70, and adjusted diluted EPS was $2.03.

1. 01

   The company said net sales for Q3 2025 rose $879 million, or 10% on a reported basis and 5% organically. Diluted EPS was $1.70, and adjusted diluted EPS was $2.03.

2. 02

   IDEX said organic sales for Q3 rose 10% in Health & Science Technologies and 4% in Fluid & Metering Technologies, and fell 5% in Fire & Safety/Diversified Products. Adjusted EBITDA margin was 27.7%, 33.7% and 27.1%, respectively.

3. 03

   The company said operating cash flow for Q3 was $203.5 million, and free cash flow was $188.7 million. On a 9-month basis, operating cash flow was $470.9 million and free cash flow was $427.0 million.

4. 04

   IDEX said it used $75 million for share repurchases in Q3 2025, $175 million year to date, and raised its share repurchase authorization to $1 billion. It narrowed its full-year GAAP diluted EPS outlook to $6.35 to $6.40 and its adjusted diluted EPS outlook to $7.86 to $7.91.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.